IDEXX Laboratories, Inc. $IDXX Shares Bought by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 52.4% in the first quarter, Holdings Channel.com reports. The institutional investor owned 838,839 shares of the company’s stock after buying an additional 288,471 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in IDEXX Laboratories were worth $471,335,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Signature Equity Partners LLC grew its stake in IDEXX Laboratories by 412.8% during the 1st quarter. Signature Equity Partners LLC now owns 241 shares of the company’s stock valued at $135,000 after acquiring an additional 194 shares in the last quarter. Alesco Advisors LLC An ESL Co purchased a new position in IDEXX Laboratories in the 1st quarter worth approximately $292,000. ABN Amro Investment Solutions lifted its stake in IDEXX Laboratories by 7.6% in the 1st quarter. ABN Amro Investment Solutions now owns 3,790 shares of the company’s stock worth $2,130,000 after purchasing an additional 268 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of IDEXX Laboratories by 5.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 45,739 shares of the company’s stock worth $25,700,000 after purchasing an additional 2,355 shares during the last quarter. Finally, Johnson Financial Group Inc. boosted its holdings in shares of IDEXX Laboratories by 2,994.4% during the 1st quarter. Johnson Financial Group Inc. now owns 1,671 shares of the company’s stock worth $939,000 after purchasing an additional 1,617 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Down 1.0%

Shares of IDXX stock opened at $539.36 on Friday. IDEXX Laboratories, Inc. has a 1-year low of $518.55 and a 1-year high of $769.98. The firm has a market cap of $42.54 billion, a PE ratio of 39.72, a price-to-earnings-growth ratio of 2.98 and a beta of 1.55. The company has a 50-day moving average of $555.96 and a two-hundred day moving average of $595.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter last year, the firm earned $2.91 EPS. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of analyst reports. Citigroup assumed coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. UBS Group cut their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Finally, Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.